hGH Fragment 176-191
Enhances Fat Metabolism
1.250.000 ₫
Delivery method:
Single vial
1.250.000 ₫
hGH pen
1.625.000 ₫
hGH Fragment 176-191 is the C-terminal segment of human growth hormone — the portion responsible for the lipolytic (fat-burning) effect of GH, isolated away from the growth-promoting and glucose-disrupting portions of the full molecule. In preclinical work it stimulates lipolysis and inhibits lipogenesis in adipocytes without affecting blood glucose, insulin sensitivity or IGF-1 — meaning it can be run alongside other GH-axis tools or during cutting blocks without the carb intolerance that full-molecule GH or strong GHRH analogs sometimes produce. Positioned as a targeted fat-loss adjunct rather than a body-composition primary driver. Most users run 250–500mcg daily SubQ, often pre-fasted cardio, in 6–8 week cutting blocks. 5mg vial.
Dosage
Start 0.25mg once daily fasted; after 1 week double to 0.25mg twice daily (research range 250–500µg/day)
Duration of effect
Daily dosing; fat-loss benefits build over weeks (plasma half-life: ~30 minutes)
See full half-life table →Key Features
- Targeted fat loss
- No blood sugar impact
- Enhanced lipolysis
- Body recomposition
Includes key details, half-life data, usage notes and research sources.
Usage Instructions
Subcutaneous injection as recommended. Consult a healthcare professional for protocols tailored to your goals.
Research Highlights
- Backed by scientific research
- Manufactured to pharmaceutical standards
- Used in clinical research settings
- Established safety profile
Safety Information
- •Consult your healthcare provider before use
- •Not intended for pregnant or nursing women
- •Store properly according to instructions
- •Report any adverse effects to your healthcare provider
Source: Obesity Research - ResearchGate
Clinical Research
hGH Fragment 176-191 increased lipolysis by 12.5 times without affecting glucose tolerance or insulin sensitivity.
Read full studyAdditional Research
Source: Stier et al., Journal of Endocrinology & Metabolism (2013)
Open-access human safety and tolerability trial of the hexadecapeptide AOD9604 (a 16-aa fragment of HGH 176-191 lineage): well tolerated at oral doses up to 54 mg/day with no GH-axis effects — supporting separation of fat-mobilising activity from full-length GH side effects.
Read full studyHuman Clinical Trials
- AOD9604 safety programmeJournal of Endocrinology and Metabolism · 2013
Summary of six randomised, double-blind, placebo-controlled trials: the safety profile was indistinguishable from placebo.
Safety and tolerability — not a weight-loss efficacy result.
Read the trial~900participants